Bar-Zeev, Naor;for the VACSURV Consortium;Tate, Jacqueline E.;for the VACSURV Consortium;Pecenka, Clint;for the VACSURV Consortium;Chikafa, Jean;for the VACSURV Consortium;Mvula, Hazzie;for the VACSURV Consortium;Wachepa, Richard;for the VACSURV Consortium;Mwansambo, Charles;for the VACSURV Consortium;Mhango, Themba;for the VACSURV Consortium;Chirwa, Geoffrey;for the VACSURV Consortium;Crampin, Amelia C.;for the VACSURV Consortium;Parashar, Umesh D.;for the VACSURV Consortium;Costello, Anthony;for the VACSURV Consortium;Heyderman, Robert S.;for the VACSURV Consortium;French, Neil;for the VACSURV Consortium;Atherly, Deborah;for the VACSURV Consortium;Cunliffe, Nigel A.;for the VACSURV Consortium;for the VACSURV Consortium;Beard, James;Iturriza-Gomara, Miren;Jere, Khuzwayo;King, Carina;Lewycka, Sonia;Nakagomi, Osamu;Phiri, Tambosi;Verani, Jennifer R.;Whitney, Cynthia G.;
clinical infectious diseases
2016
Vol. 62
pp. S220-S228
216
naor2016clinicalcost-effectiveness